Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach

Prostate

Volumn 69, Issue 8, 2009, Pages 827-837

  Kawasaki, Brian T ^a   Hurt, Elaine M ^a   Kalathur, Madhuri ^a   Duhagon, Maria Ana ^a,b   Milner, John A ^c   Kim, Young S ^c   Farrar, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer stem cells; Parthenolide; Phytonutrient; Prostate

Indexed keywords

BETA ARRESTIN 1; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CCAAT ENHANCER BINDING PROTEIN ALPHA; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FOCAL ADHESION KINASE; HERMES ANTIGEN; HOMEODOMAIN 4 PROTEIN; HOMEODOMAIN PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PARTHENOLIDE; PROTEIN C MYB; PROTEIN KINASE C; PROTEIN P53; PROTEIN TYROSINE KINASE; SERUM RESPONSE FACTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; LEUKOCYTE ANTIGEN; RNA; SESQUITERPENE; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CARCINOGENESIS; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXICITY; GENE TARGETING; GENOMICS; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN MICROARRAY; PROTEOMICS; TUMOR XENOGRAFT; ANIMAL; DNA MICROARRAY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD44; CELL LINE, TUMOR; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; PROSTATIC NEOPLASMS; RNA, NEOPLASM; SESQUITERPENES; TRANSCRIPTION, GENETIC;

EID: 65549140597     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20931     Document Type: Article

References (58)

1. Sharifi N, Kawasaki BT, Hurt EM, Farrar WL. Stem cells in prostate cancer: Resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol Ther 2006;5:901-906.
2. Sharifi N, Kawasaki BT, Hurt EM, Farrar WL. Stem cells in prostate cancer: Resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol Ther 2006;5:901-906.
3. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284. (Pubitemid 40488633)
4. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, Jeter C. Prostate cancer stem/progenitor cells: Identification, characterization, and implications. Mol Carcinog 2007;46:1-14.
5. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-1708.
6. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44(+)CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98:756-765.
7. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-1708.
8. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-1708.
9. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284. (Pubitemid 40488633)
10. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-1421.
11. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-1421.
12. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-1421.
13. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005;105:4163-4169. (Pubitemid 40720758)
14. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 2007.
15. Hehner SP, Hofmann TG, Droge W, Schmitz ML. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol 1999;163:5617-5623.
16. Guzman ML, Jordan CT. Feverfew: Weeding out the root of leukaemia. Expert Opin Biol Ther 2005;5:1147-1152.
17. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005;105:4163-4169. (Pubitemid 40720758)
18. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 2007.
19. Hurt EM, Thomas SB, Peng B, Farrar WL. Integrated molecular profiling of SOD2 expression in multiple myeloma. Blood 2007;109:3953-3962. (Pubitemid 46641748)
20. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44(+)CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98:756-765.
21. Hurt EM, Thomas SB, Peng B, Farrar WL. Integrated molecular profiling of SOD2 expression in multiple myeloma. Blood 2007;109:3953-3962. (Pubitemid 46641748)
22. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-1708.
23. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44(+)CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98:756-765.
24. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44(+)CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98:756-765.
25. Asim M, Siddiqui IA, Hafeez BB, Baniahmad A, Mukhtar H. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene 2008.
26. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13:513-609. (Pubitemid 28034534)
27. Guzman ML, Jordan CT. Feverfew: Weeding out the root of leukaemia. Expert Opin Biol Ther 2005;5:1147-1152.
28. Yin H, Radomska HS, Tenen DG, Glass J. Down regulation of PSA by C/EBPalpha is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell line. BMC Cancer 2006;6:158. (Pubitemid 44240723)
29. Kaur M, Agarwal R. Transcription factors: Molecular targets for prostate cancer intervention by phytochemicals. Curr Cancer Drug Targets 2007;7:355-367.
30. de PG, Legrier ME, Poirson-Bichat F, Courty Y, Bras-Goncalves R, Dutrillaux AM, Nemati F, Oudard S, Lidereau R, Broqua P, Junien JL, Dutrillaux B, Poupon MF. Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. Am J Pathol 2001;159:753-764.
31. Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, Hubank MJ, Ahmed A, Masters JR. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 2007;26:6560-6565. (Pubitemid 47530597)
32. Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W, Yeung KC. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 2007.
33. Heemers HV, Regan KM, Dehm SM, Tindall DJ. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: Evidence for a role for serum response factor in prostate cancer. Cancer Res 2007;67:10592-10599.
34. Takahashi S, Suzuki S, Inaguma S, Ikeda Y, Cho YM, Nishiyama N, Fujita T, Inoue T, Hioki T, Sugimura Y, Ushijima T, Shirai T. Down-regulation of human X-box binding protein 1 (hXBP-1) expression correlates with tumor progression in human prostate cancers. Prostate 2002;50:154-161. (Pubitemid 34137442)
35. de PG, Legrier ME, Poirson-Bichat F, Courty Y, Bras-Goncalves R, Dutrillaux AM, Nemati F, Oudard S, Lidereau R, Broqua P, Junien JL, Dutrillaux B, Poupon MF. Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. Am J Pathol 2001;159:753-764.
36. Horinaga M, Okita H, Nakashima J, Kanao K, Sakamoto M, Murai M. Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology 2005;66:671-675. (Pubitemid 41242358)
37. Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 1999;18:6322-6329. (Pubitemid 29229563)
38. Herawi M, De Marzo AM, Kristiansen G, Epstein JI. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate. Hum Pathol 2007;38:72-78.
39. Xiao W, Hodge DR, Wang L, Yang X, Zhang X, Farrar WL. Co-operative functions between nuclear factors NFkappaB and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 2004;61:354-370. (Pubitemid 39564278)
40. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. Expression and role of Foxa proteins in prostate cancer. Prostate 2006;66:1013-1028. (Pubitemid 43939204)
41. Dwivedi PP, Anderson PH, Omdahl JL, Grimes HL, Morris HA, May BK. Identification of growth factor independent-1 (GFI1) as a repressor of 25-hydroxyvitamin D 1-alpha hydroxylase (CYP27B1) gene expression in human prostate cancer cells. Endocr Relat Cancer 2005;12:351-365. (Pubitemid 40896452)
42. Edlund S, Lee SY, Grimsby S, Zhang S, Aspenstrom P, Heldin CH, Landstrom M. Interaction between Smad7 and beta-catenin: Importance for transforming growth factor beta-induced apoptosis. Mol Cell Biol 2005;25:1475-1488.
43. Kaur M, Agarwal R. Transcription factors: Molecular targets for prostate cancer intervention by phytochemicals. Curr Cancer Drug Targets 2007;7:355-367.
44. Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, Hubank MJ, Ahmed A, Masters JR. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 2007;26:6560-6565. (Pubitemid 47530597)
45. Guzman ML, Jordan CT. Feverfew: Weeding out the root of leukaemia. Expert Opin Biol Ther 2005;5:1147-1152.
46. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007;18:1765-1773. (Pubitemid 350119560)
47. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002;347:1593-1603. (Pubitemid 35315841)
48. Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci 2008;13:1857-1865.
49. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007;18:1765-1773. (Pubitemid 350119560)
50. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 2007;9:90-100. (Pubitemid 46318376)
51. Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, Mundy GR, Yoneda T. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003;63:5028-5033. (Pubitemid 37022641)
52. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007;18:1765-1773. (Pubitemid 350119560)
53. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007;18:1765-1773. (Pubitemid 350119560)
54. Sweeney CJ, Mehrotra S, Sadaria MR, Kumar S, Shortle NH, Roman Y, Sheridan C, Campbell RA, Murry DJ, Badve S, Nakshatri H. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther 2005;4:1004-1012. (Pubitemid 40909083)
55. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007;110:4427-4435.
56. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007;110:4427-4435.
57. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284. (Pubitemid 40488633)
58. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004;14:43-47. (Pubitemid 38167476)